FACULTY
Michael R. Grunwald, MD
Chief, Leukemia Division
Associate Professor, Atrium Health
Department of Hematologic Oncology and Blood
Disorders
Levine Cancer Institute
Charlotte, NC
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
PROGRAM OVERVIEW
This online activity will cover the treatment and management of patients with AML and CLL.
TARGET AUDIENCE
This activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in
the treatment of CLL and AML.
LEARNING OBJECTIVES
On completing this program, attendees should be able to:
- Explain how common mutations and abnormalities in patients with previously untreated and relapsed/refractory
(R/R) CLL and AML affect treatment decision-making - Describe available and emerging therapeutic approaches for patients with previously untreated and R/R CLL and
AML - Review methods for measuring and analyzing minimal residual disease (MRD) in CLL and clinical trial data
providing insight into the use of MRD status in the management of CLL - Design evidence-based therapeutic strategies for patients with previously untreated and R/R CLL and AML based on
patient characteristics - Discuss the benefits of effective communication between health care providers and patients with previously
untreated and R/R CLL and AML
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 2.0 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the treatment and management of patients with AML and CLL.
CNE Credits:
2.0 ANCC Contact Hours
CNE ACCREDITATION STATEMENTS:
Ultimate Medical Academy/Completed Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 2.0 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial
Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity,
and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an
MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the
manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an
educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Michael Grunwald has received consultant fees from Incyte, BMS/Celgene, Pfizer, Cardinal Health,
Amgen, Merck, Agios, AbbVie, Daiichi Sankyo, Trovagene, Astellas, and Premier, and received fees for non-CME
services from Incyte. He has been contracted for research for Amgen, Incyte, Genentech/Roche, Janssen, Forma
Therapeutics, and Novartis. He has ownership interest in Medtronic.
Dr. Ryan Jacobs has served on the speakers’ bureau for AbbVie, AstraZeneca, Pharmacyclics, Genentech, Janssen, and Verastem. He has received consultant fees from AbbVie, Pharmacyclics, Verastem, and AstraZeneca. He has received research funding from Pharmacyclics and TG Therapeutics.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Marcello Morgan, MD, MPH, Scientific and Medical Services for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing
any unlabeled or investigational use of any commercial product or device not yet approved for use in the United
States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the activity.
- Complete pre-and post surveys and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: August 14, 2020
EXPIRATION DATE: August 14, 2021
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at
[email protected]
